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radiotherapy in human cancer models in vitro and in mouse 
xenografts.  
 
Conclusion: Conclusion: GRP78 is a molecular target for the 
development of novel radiation sensitizing agents. Anti-
GRP78 antibodies enhance the efficacy of radiotherapy when 
administered IV to mouse models of human cancer. 
 
 
Poster: Radiobiology track: Tumour biology and 
microenvironment  
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Purpose or Objective: The objective of this study was to 
investigate the biological role of miR-143 in esophageal 
squamous cell carcinoma (ESCC) progression and its 
underlying mechanism. 
 
Material and Methods: Surgical tumor tissue samples were 
obtained from 40 patients. MiR-143 and STAT3 protein 
expression levels in these clinical samples and three ESCC 
cell lines were determined by quantitative RT–PCR and 
western blot. The relationship between expression level of 
miR-143 and clinical parameters were explored by one-way 
ANOVA. The specific targeting site of miR-143 in the 3’-UTR 
of STAT3 was identified using dual-luciferase reporter assays. 
Then, the effects of ectopic miR-143 or STAT3 expression on 
proliferation, cell cycle distribution, migration and invasion 
were determined in colony-forming assay, flow cytometry 
and transwell assay. The effect of miR-432 on tumor 
progression in vivo was determineded by performing tumor 
formation assay in nude mice. The role miR-143 in regulating 
cell cycle signaling, epithelial-mesenchymal transition and 
MMP up-regulation through repressing STAT3 was explored by 
analyzing the expression level of the downstream proteins. 
 
Results: MiR-143 expression was downregulated in 90% of the 
ESCC clinical samples and its expression level was associated 
with the lymph node metastasis(LNM), invasion and TNM 
stage in ESCC patients. Functional experiments showed that 
ectopic expression of miR-143 could inhibit tumor cell 
proliferation, migration and invasion by supressing STAT3 in 
vitro. Animal experiments showed that the size of 
subcutaneous tumors derived from miR-143 overexpressing 
cells were significantly smaller than that of empty vector 
expressing cells. Further studies verified that miR-143 might 
regulate cell cycle, EMT and MMP up-regulation by targeting 
STAT3 and hence, lead to the suppresion of ESCC cell 
proliferation, migration and invasion. 
 
Conclusion: Our study showed that miR-143 could act as a 
tumor suppressor through the inhibition of proliferation, 
migration and invasion by directly targeting STAT3 and 
subsequently mediates the downstream proteins. Thus, miR-
143 has significant value in clinical and may serve as a 
prognostic marker and therapeutic target in the future. 
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Purpose or Objective: The objective of this study was to 
investigate the biological role of miR-432 in esophageal 
squamous cell carcinoma (ESCC) progression and its 
underlying mechanism. 
 
Material and Methods: Surgical tumor specimens and 
adjacent tissue samples were obtained from 40 patients. 
Pearson correlation coefficients and linear regression model 
were used to explore the bivariate correlations between miR-
432 and IGSF3 expression levels and one-way ANOVA were 
used to estimate the relationship between expression level of 
miR-432 and clinical parameters. Then the effects of ectopic 
miR-432 or IGSF3 expression on proliferation and apoptosis 
were determined using miR-432 over-expression or 
knockdown cells in colony-forming assay and flow cytometry, 
and the effects on cell migration and invasion were 
determined using a transwell assay. On the other hand, 
bioinformatic analysis were performed to assess the 
relationship between IGSF3 and miR-432, and this 
relationship was identified using a dual-luciferase reporter 
assay. Finally, the biological consequences of miR-432-
mediated suppression of IGSF3 expression in ESCC cell lines 
were also determined by performing colony-forming assay, 
flow cytometry and trasnswell assay. 
 
Results: MiR-432 expression was downregulated in 93% 
(37/40) of the ESCC clinical samples and its expression level 
was associated with LNM and TNM stage in ESCC patients. 
Functional experiments showed that over-expression of miR-
432 induced an inhibition of cell proliferation, promotion of 
apoptosis and suppression of cell migraion and invasion in 
vitro by targeting IGSF3. 
 
Conclusion: In conclusion, our results established a 
functional link between miR-432 and IGSF3 expression in 
esophageal cancer, demonstrating that IGSF3 was directly 
repressed by miR-432, which subsequently effects the tumor 
biological process. Collectively, this finding not only helped 
us understand the molecular mechanism of esophageal 
carcinogenesis, but also gave us a strong rationale to further 
investigate miR-432 as a potential biomarker and therapeutic 
target for esophageal cancer. 
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Purpose or Objective: Tumor cells are the major targets for 
classic anticancer treatment modalities. At the same time 
other cell types within the tumor microenvironment are also 
targeted and co-determine the treatment response. 
Resistances to specific treatment modalities are therefore 
not only linked to the mutated genetic background of the 
tumor cells but also to the interaction of tumor cells with the 
tumor microenvironment. Thus targeting of important 
elements of the microenvironment is a promising strategy to 
overcome treatment resistances in solid tumors. Here we 
mechanistically investigate in different clinically relevant 
microtubule-stabilizing agent (MSA)-refractory tumor models 
the potency of combined treatment modalities of MSAs, 
inhibitors of angiogenesis and ionizing radiation to overcome 
MSA-resistance. 
 
Material and Methods: Rationally designed single and 
combined treatment regimens of ionizing radiation, 
microtubule stabilizing (taxane, epothilone) and de-
stabilizing agents and anti-angiogenics compounds were 
investigated in genetically defined MSA-sensitive and MSA-
resistant lung and colon adenocarcinoma cell lines in vitro 
and in the corresponding tumor xenografts in vivo. 
 
Results: While MSAs potently inhibited A549wt and 
endothelial cell proliferation, no anti-proliferative effect was 
observed in the corresponding mutated MSA-resistant tumor 
cells. Importantly, MSAs did not block anymore pro-survival 
auto- and paracrine signaling from resistant tumor cells by 
downregulation of HIF1-alpha transcriptional activity and 
subsequent secretions of HIF-1alpha-mediated growth factors 
and cytokines like VEGF. Thereby continuous pro-survival 
